Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Investigators will test the value of very low dose Pazopanib administered to patients with
hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in
those with frequent and long duration bleeding episodes.